Eli Lilly has reached its first legal settlement with one of the spas that it had accused in lawsuits of infringing its trademarks by selling alternative versions of Lilly's hot-selling drugs for diabetes and weight loss.
Both Lilly and its archrival Novo Nordisk have been trying to crack down on the sale of custom-made versions of their drugs. The alternative versions have become popular because they're often cheaper than the originals, and available when the brand-name versions are in short supply.
In the settlement, Totality Medispa LLC agreed to pay an undisclosed sum to Lilly and to stop using the Lilly brand names Mounjaro and Zepbound when promoting custom-made, or compounded, versions of the drugs.